Losartan Potassium Tablet, Film Coated
Product Images NDC 72603-340

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 72603-340). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northstar Rxllc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Losartanpotassiumfigure1 (Losartanpotassiumfigure1)

A line graph comparing the percentage of patients with the primary endpoint over a 66-month study period between Atenolol and Losartan Potassium. The y-axis shows the percentage of patients, and the x-axis shows the study months. Both lines increase over time with Atenolol slightly higher. The graph notes an adjusted risk reduction of 13% with a p-value of 0.021.*

FDA Label Image

Losartanpotassiumfigure2 (Losartanpotassiumfigure2)

A line chart comparing the percentage of patients with fatal/non-fatal stroke over study months for Atenolol and Losartan potassium. The chart shows Losartan potassium with a consistently lower percentage than Atenolol, indicating a 25% adjusted risk reduction with statistical significance (p=0.001).*

FDA Label Image

Losartanpotassiumfigure3 (Losartanpotassiumfigure3)

A forest plot showing hazard ratios with 95% confidence intervals comparing Losartan Potassium and Atenolol for primary composite and stroke (fatal/non-fatal) event rates. The chart displays subgroup analyses by age, gender, race, isolated systolic hypertension (ISH), diabetes, and history of cardiovascular disease (CVD), with event rates and number of patients for each group. The plot visually indicates which treatment each subgroup favors based on hazard ratio values.*

FDA Label Image

Losartanpotassiumfigure4 (Losartanpotassiumfigure4)

A line graph comparing the percentage of patients experiencing an event over 48 months for Losartan Potassium versus Placebo. The graph shows cumulative event rates increasing over time, with Losartan Potassium demonstrating a 16.1% risk reduction compared to Placebo, noted with a p-value of 0.022. The x-axis represents time in months, and the y-axis shows the percentage of patients with the event.*

FDA Label Image

Losartanpotassiumlabel100mg90s (Losartanpotassiumlabel100mg90s)

Losartan Potassium Tablets USP 100 mg film coated, supplied in a 90 tablet container. The label includes storage instructions (20° to 25°C), manufacturer information (NorthStar Rx LLC, Memphis, TN), and manufacturing by Hetero Labs Limited, India. Barcode and batch coding area are also visible.*

FDA Label Image

Losartanpotassiumlabel25mg90s (Losartanpotassiumlabel25mg90s)

Losartan Potassium Tablets USP 25 mg film coated tablets label for a 90 count bottle. The label includes the NDC 72603-340-01 and states storage instructions, warnings, and manufacturing information. It is manufactured for Northstar Rx LLC and indicates the active ingredient strength as 25 mg per tablet.*

FDA Label Image

Losartanpotassiumlabel50mg90s (Losartanpotassiumlabel50mg90s)

Label for Losartan Potassium Tablets USP 50 mg film-coated tablets in a 90-tablet package. The label includes storage instructions, a barcode, manufacturer details (NorthStar Rx LLC and Hetero Labs Limited, India), and a batch coding area. The label is predominately white and blue with green highlighting the 50 mg strength.*

FDA Label Image

Losartanpotassiumstructure (Losartanpotassiumstructure)

Chemical structure of Losartan Potassium, showing its distinct chemical groups including a chlorinated biphenyl group, a tetrazole ring, and a potassium ion.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.